Synonyms: Revuforj® | SNDX-5613 | SNDX5613
revumenib is an approved drug (FDA (2024))
Compound class:
Synthetic organic
Comment: The chemical structure for revumenib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as an antineoplastic agent. It resolved to Syndax Pharmaceuticals' SNDX-5613 via a PubChem match on SMILES. SNDX-5613 inhbits the Menin-KMT2A protein-protein interaction (binding directly to menin), as a strategy that was originally proposed to treat acute leukemias that are driven by proleukemogenic KMT2A rearrangements [1].
Additional menin inhibitors in development include bleximenib (JNJ-75276617), ziftomenib (KO-539), emilumenib (DS-1594a), enzomenib (DSP-5336) and icovamenib (BMF-219). |
|